Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00893334 · ClinicalTrials.gov registry record
Evaluation of Limb-Girdle Muscular Dystrophy
A clinical trial of Becker Muscular Dystrophy and Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency), sponsored by Cooperative International Neuromuscular Research Group.
- Completed
- Registry status
- 60
- Enrollment target
- 2
- Study locations
NCT00893334 is a study of Becker Muscular Dystrophy and Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency) that has completed, run by Cooperative International Neuromuscular Research Group. The registered enrollment target is 60 participants, below the 1,391-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00893334, a study of Becker Muscular Dystrophy and Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency), has completed, sponsored by Cooperative International Neuromuscular Research Group.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand the biochemistry of different types of Limb-Girdle Muscular Dystrophy (LGMD) and to determine appropriate outcome measures for future clinical treatment trials for LGMD. It is being conducted at two sites in the Cooperative International Neuromuscular Research Group (CINRG). It involves a one day clinical evaluation at a participating institution that will take approximately four to six hours, and will involve strength testing and muscle functional testing by a physical therapist, an evaluation by a physician, pulmonary function testing, a complete cardiac evaluation with electrocardiogram (ECG or EKG) and echocardiogram (Echo), and involve two blood draws, one before the evaluation and one after the evaluation is complete. During the visit, the participant will be asked to fill out a couple of questionnaires asking questions about quality of life and activity limitations, as well as his/her understanding of their diagnosis with regards to etiology (or cause of their muscle disorder), genetics, and inheritance of their muscle disorder.
Conditions Studied
Study Locations (2)
District of Columbia
- Children's National Medical Center - Washington D.C.
North Carolina
- Carolinas Medical Center - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00893334
The ClinicalTrials.gov registry entry for NCT00893334 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,391-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (96% lower). The listed sponsor is Cooperative International Neuromuscular Research Group, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Becker Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT00893334 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00893334 about?
NCT00893334 is a clinical study titled "Evaluation of Limb-Girdle Muscular Dystrophy". The purpose of this study is to understand the biochemistry of different types of Limb-Girdle Muscular Dystrophy (LGMD) and to determine appropriate outcome measures for future clinical treatment trials for LGMD. It is being conducted at two sites in the Cooperative International Neuromuscular Resea...
What is the current status of trial NCT00893334?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2009-04. Estimated completion is 2013-12.
What conditions does trial NCT00893334 study?
This clinical trial studies the following conditions: Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency), Limb-Girdle Muscular Dystrophy, Type 2B (Miyoshi Myopathy, Dysferlin Deficiency), Limb-Girdle Muscular Dystrophy, Type 2I (FKRP-deficiency).
Who is sponsoring clinical trial NCT00893334?
This trial is sponsored by Cooperative International Neuromuscular Research Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00893334 being conducted?
This trial has 2 study locations across District of Columbia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Becker Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Duchenne Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
RECRUITING
-
CureDuchenne Link®: A Resource for Research
RECRUITING
-
Defining Endpoints in Becker Muscular Dystrophy
ACTIVE NOT RECRUITING
-
Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Becker Muscular Dystrophy
All registered trials for this condition
Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency)
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.